Phase 3 Migraine Trial, Recruiting NCT06616194 Sponsor: Pfizer Condition: Migraine
Back to Migraine

Phase 3 Migraine Trial, Recruiting

NCT06616194
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had migraines (with or without aura) for at least 6 months.
  • People who experience 15 or more headache days per month.
  • People who experience 8 or more migraine days per month.
  • People whose migraines typically last between 4 and 72 hours when left untreated.

Who may not be able to join:

  • People who have a headache that never goes away or stops.
  • People who have a psychiatric condition that is not being treated or is not under control.
  • People who have a history of suicidal behaviour or who are currently considered at risk of self-harm.
  • People who have a history of alcohol abuse or use of illegal drugs.
  • People who have a history of severe allergic reactions to medication.
  • People who are currently using more than one medication to prevent migraines.
  • People who are currently taking part in another clinical trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
15 November 2024
Est. completion
8 October 2026

Where this trial is recruiting

🇨🇦 Canada 🇨🇳 China 🇨🇿 Czechia 🇫🇮 Finland 🇭🇺 Hungary 🇮🇳 India 🇮🇹 Italy 🇯🇵 Japan 🇵🇱 Poland 🇸🇰 Slovakia 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Number of migraine days per month

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov